Get the Stockscreener App
26.19
1.39%
0.36
Arcutis Biotherapeutics Inc stock is traded at $26.19, with a volume of 1.11M.
It is up +1.39% in the last 24 hours and down -2.31% over the past month.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
See More
Previous Close:
$25.83
Open:
$25.39
24h Volume:
1.11M
Relative Volume:
0.65
Market Cap:
$3.29B
Revenue:
$415.62M
Net Income/Loss:
$-2.38M
P/E Ratio:
-922.18
EPS:
-0.0284
Net Cash Flow:
$16.92M
1W Performance:
+3.56%
1M Performance:
-2.31%
6M Performance:
+1.28%
1Y Performance:
+63.89%
1-Day Range:
$25.28
$26.23
1-Week Range:
$24.76
$26.82
52-Week Range:
$15.10
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
26.19 | 3.30B | 415.62M | -2.38M | 16.92M | -0.0284 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Liquidity Mapping Around (ARQT) Price Events - Stock Traders Daily
Polar Capital discloses 5.28% Arcutis Biotherapeutics (ARQT) ownership in Schedule 13G - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals - ChartMill
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Patrick Burnett Sells 6,700 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Patrick Burnett Sells 8,300 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock - Investing.com
Bank of America Corp DE Acquires 547,835 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis insider plans sale of 15,000 shares | ARQT SEC FilingForm 144 - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup - ChartMill
HC Wainwright Analysts Boost Earnings Estimates for ARQT - MarketBeat
ARQT Technical Analysis & Stock Price Forecast - Intellectia AI
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
24 New Arcutis Employees Get Stock Awards That Vest Over Four Years - Stock Titan
State Street Corporation (ARQT) discloses 4.7% beneficial stake in Arcutis - Stock Titan
Analysts Set Expectations for ARQT Q1 Earnings - MarketBeat
Arcutis Biotherapeutics EVP Matsuda sells $32,123 in stock By Investing.com - Investing.com South Africa
Guggenheim raises Arcutis stock price target on strong Zoryve sales By Investing.com - Investing.com South Africa
Arcutis CEO Todd Watanabe sells $114,261 of ARQT stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics EVP Burnett sells $24,941 in stock By Investing.com - Investing.com South Africa
ARQT Maintains Overweight Rating -- Price Target Raised to $38.0 - GuruFocus
Arcutis Biotherapeutics (NASDAQ:ARQT) Given New $40.00 Price Target at Needham & Company LLC - MarketBeat
Arcutis Biotherapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ARQT) 2026-08-06 - Seeking Alpha
Did Profitability, Higher 2026 Guidance, and New Commercial Leadership Just Recast Arcutis Biotherapeutics' (ARQT) Investment Narrative? - simplywall.st
ARQT Maintained by Guggenheim -- Price Target Raised to $38 - GuruFocus
Arcutis Biotherapeutics EVP Matsuda sells $32,123 in stock - Investing.com
Guggenheim raises Arcutis stock price target on strong Zoryve sales - Investing.com
Arcutis Biotherapeutics EVP Burnett sells $24,941 in stock - Investing.com
Form 4 Arcutis Biotherapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
ARQT Maintains Buy Rating by Needham -- Price Target Raised to $40 - GuruFocus
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability - The Motley Fool
Arcutis Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $36.62, Implies 35% Upside - TradingView
Arcutis CEO Todd Watanabe sells $114,261 of ARQT stock - Investing.com
Arcutis Biotherapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Sei Investments Co. Has $4.86 Million Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Inc (ARQT) (Q2 2026) Earnings Call Highl - GuruFocus
Arcutis Biotherapeutics Inc (ARQT) (Q2 2026) Earnings Call Highlights: Revenue Surges 59% and ... - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Patrick Burnett Sells 955 Shares of Stock - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $114,275.00 in Stock - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $32,127.60 in Stock - MarketBeat
Earnings call transcript: Arcutis Biotherapeutics tops Q2 2026 revenue view By Investing.com - Investing.com Nigeria
Earnings call transcript: Arcutis Biotherapeutics tops Q2 2026 revenue view - Investing.com
Is Arcutis Biotherapeutics (ARQT) Undervalued After Q2 Earnings - GuruFocus
Arcutis Q2 2026 slides: profitability achieved, revenue guidance raised - Investing.com
Arcutis Biotherapeutics Q2 Earnings Call Highlights - MarketBeat
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Arcutis Biotherapeutics (NASDAQ:ARQT) Announces Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Arcutis Biotherapeutics, Inc. 2026: Revenue $129.86M, EPS $0.11— 10-Q Summary - TradingView
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):